You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR INDIUM IN-111 PENTETREOTIDE KIT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for INDIUM IN-111 PENTETREOTIDE KIT

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001849 ↗ New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 2 1999-05-20 Cushing Syndrome is an endocrine disorder causing an over production of the hormone cortisol. Cortisol is produced in the adrenal gland as a response to the production of corticotropin (ACTH) in the pituitary gland. Between 10% and 20% of patients with hypercortisolism (Cushing Syndrome) have ectopic production of the hormone ACTH. Meaning, the hormone is not being released from the normal site, the pituitary gland. In many cases the ectopic ACTH is being produced by a tumor of the lung, thymus, or pancreas. However, in approximately 50% of these patients the source of the ACTH cannot be found even with the use of extensive imaging studies such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and nuclear scans (111-indium pentetreotide). The ability of these tests to locate the source of the hormone production is dependent on the changes of anatomy and / or the dose and adequate uptake of the radioactive agent. The inability to detect the source of ectopic ACTH production often results in unnecessary pituitary surgery or irradiation. Unlike the previously described tests, positron emission tomography (PET scan) has the ability to detect pathologic tissue based on physiologic and biochemical processes within the abnormal tissue. This study will test whether fluorine-18-fluorodeoxyglucose (FDG), fluorine-18-dihydroxyphenylalanine (F-DOPA) or use of a higher dose of 111-indium pentetreotide can be used to successfully localize the source of ectopic ACTH production.
NCT00442533 ↗ Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed CHI St. Luke's Health, Texas Phase 2/Phase 3 2005-08-01 The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
NCT00442533 ↗ Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed Excel Diagnostic Imaging Clinics Phase 2/Phase 3 2005-08-01 The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
NCT00442533 ↗ Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed RadioMedix Phase 2/Phase 3 2005-08-01 The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
NCT00442533 ↗ Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed Radiomedix, Inc. Phase 2/Phase 3 2005-08-01 The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
NCT00442533 ↗ Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed Radio Isotope Therapy of America Phase 2/Phase 3 2005-08-01 The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for INDIUM IN-111 PENTETREOTIDE KIT

Condition Name

Condition Name for INDIUM IN-111 PENTETREOTIDE KIT
Intervention Trials
Cushing Syndrome 2
Neuroendocrine Tumors 2
ACTH 1
Carcinoid Tumors 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for INDIUM IN-111 PENTETREOTIDE KIT
Intervention Trials
Neuroendocrine Tumors 3
Carcinoid Tumor 3
Cushing Syndrome 2
Cardiac Complexes, Premature 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for INDIUM IN-111 PENTETREOTIDE KIT

Trials by Country

Trials by Country for INDIUM IN-111 PENTETREOTIDE KIT
Location Trials
United States 4
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for INDIUM IN-111 PENTETREOTIDE KIT
Location Trials
Maryland 2
Iowa 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for INDIUM IN-111 PENTETREOTIDE KIT

Clinical Trial Phase

Clinical Trial Phase for INDIUM IN-111 PENTETREOTIDE KIT
Clinical Trial Phase Trials
Phase 2/Phase 3 1
Phase 2 2
Phase 1/Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for INDIUM IN-111 PENTETREOTIDE KIT
Clinical Trial Phase Trials
Completed 3
Recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for INDIUM IN-111 PENTETREOTIDE KIT

Sponsor Name

Sponsor Name for INDIUM IN-111 PENTETREOTIDE KIT
Sponsor Trials
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 2
SWAN Isotopen AG, Bern 1
University Hospital, Basel, Switzerland 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for INDIUM IN-111 PENTETREOTIDE KIT
Sponsor Trials
Other 10
NIH 3
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.